SPY772.04+0.09%QQQ745.40+0.12%BTC/USD83,231.14−1.44%DIA517.72+0.04%GLD393.05−0.09%TLT79.38+0.08%
Benzinga

Arvinas Inc (ARVN) Stock Price, Quote, News & History

ARVNNASDAQ
Trade with Public
Trade with Public
$7.59
-0.20-2.57%
At close: Sep 25, 5:00 PM EST
$7.59
N/A
After Hours: Sep 25, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Arvinas (ARVN) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$7.78
Close
$7.59
Volume / Avg.
713.36K / 818.83K
Day Range
$7.54 - $7.81
52 Wk Range
6.97 - 14.51
Market Cap
$496.28M
P/E Ratio
30.00
Dividend Yield
-
Exchange
NASDAQ
RSI
31
Short Interest
8.89%
Days to Cover
5.59

Recent Arvinas, Inc. News

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.
Avi Kapoor

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including upgrades/downgrades, see our analyst ratings page.
Avi Kapoor

Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.
Vandana Singh

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment for ESR1-mutated advanced breast cancer.
Vandana Singh

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday

Avi Kapoor
80%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-207.00M
Investing Cash Flow (TTM)
277.90M
Financing Cash Flow (TTM)
-91.50M
Free Cash Flow (TTM)
-208.80M
Capital Expenditure (TTM)
-1.80M
Net Change in Cash (TTM)
-20.60M

Analyst Trends and Forecast

3
May
1
Jun
3
2
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
-$63.62M
PE Ratio (TTM)
30.00
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
1.66
PB Ratio (TTM)
0.91
Earnings Yield % (TTM)
3.33%
Earnings Yield % (FWD)
-30.26%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$8.60

Company Debt

Total Debt
$300.00K
LT Debt
$300.00K
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$300.00K
Total Cash
$94.30M
Debt to Equity
0.01
Issuance of Debt (TTM)
-$300.00K
Repayment of Debt (TTM)
-$300.00K

Key Statistics

Open
$7.78
Close
$7.59
Volume / Avg.
713.36K / 818.83K
Day Range
$7.54 - $7.81
52 Wk Range
6.97 - 14.51
Market Cap
$496.28M
P/E Ratio
30.00
Dividend Yield
-
Exchange
NASDAQ
RSI
31
Short Interest
8.89%
Days to Cover
5.59

About

Sector
Health Care
Industry
Pharmaceuticals
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-cau...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

Q

How do I buy Arvinas (ARVN) stock?

A

You can purchase shares of Arvinas (NASDAQ:ARVN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Arvinas (ARVN) competitors?

Q

What is the forecast, or price target, for Arvinas (ARVN) stock?

A

Arvinas has a consensus price target of $19.60.

Q

What is the current price for Arvinas (ARVN)?

A

The stock price for Arvinas (NASDAQ: ARVN) is $7.59 last updated September 25, 2026 at 4:00 PM EDT.

Q

Does Arvinas (ARVN) pay a dividend?

A

There are no upcoming dividends for Arvinas.

Q

When is Arvinas (NASDAQ:ARVN) reporting earnings?

A

Arvinas does not have any upcoming earnings scheduled.

Q

Is Arvinas (ARVN) going to split?

A

There is no upcoming split for Arvinas.

Q

What sector and industry does Arvinas (ARVN) operate in?

A

Arvinas is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved